These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17498411)

  • 1. Patch testing for evaluating drug reactions due to systemic antibiotics.
    Cham PM; Warshaw EM
    Dermatitis; 2007 Jun; 18(2):63-77. PubMed ID: 17498411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing.
    El Khoury M; Assier H; Gener G; Paul M; Haddad C; Chosidow O; Wolkenstein P; Ingen-Housz-Oro S
    Br J Dermatol; 2018 Oct; 179(4):978-979. PubMed ID: 29747236
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous adverse reactions to clindamycin: results of skin tests and oral exposure.
    Lammintausta K; Tokola R; Kalimo K
    Br J Dermatol; 2002 Apr; 146(4):643-8. PubMed ID: 11966697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clindamycin-associated acute generalized exanthematous pustulosis.
    Valois M; Phillips EJ; Shear NH; Knowles SR
    Contact Dermatitis; 2003 Mar; 48(3):169. PubMed ID: 12755740
    [No Abstract]   [Full Text] [Related]  

  • 5. Patch testing for drugs.
    Aquino MR; Sher J; Fonacier L
    Dermatitis; 2013; 24(5):205-14. PubMed ID: 24030368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?
    Monteagudo B; Cabanillas M; Iriarte P; Ramírez-Santos A; León-Muinos E; González-Vilas D; Suárez-Amor Ó
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):61-63. PubMed ID: 29782303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of patch tests in pristinamycin-induced drug eruptions.
    Mayence C; Dompmartin A; Verneuil L; Michel M; Leroy D
    Contact Dermatitis; 1999 Mar; 40(3):161-2. PubMed ID: 10073448
    [No Abstract]   [Full Text] [Related]  

  • 8. Utility of patch testing for the diagnosis of delayed-type drug hypersensitivity reactions to clindamycin.
    Gilissen L; Huygens S; Goossens A; Breynaert C; Schrijvers R
    Contact Dermatitis; 2020 Sep; 83(3):237-239. PubMed ID: 32333605
    [No Abstract]   [Full Text] [Related]  

  • 9. Skin tests in the diagnosis of eruptions caused by betalactams.
    Lisi P; Lapomarda V; Stingeni L; Assalve D; Hansel K; Caraffini S; Agostinelli D
    Contact Dermatitis; 1997 Oct; 37(4):151-4. PubMed ID: 9385509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of patch tests in clindamycin-related drug eruptions.
    Pereira N; Canelas MM; Santiago F; Brites MM; Gonçalo M
    Contact Dermatitis; 2011 Oct; 65(4):202-7. PubMed ID: 21689110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins.
    Barbaud A; Trechot P; Weber-Muller F; Ulrich G; Commun N; Schmutz JL
    Contact Dermatitis; 2004 Jan; 50(1):22-6. PubMed ID: 15059099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occupational allergic contact dermatitis caused by antibiotics in healthcare workers - relationship with non-immediate drug eruptions.
    Pinheiro V; Pestana C; Pinho A; Antunes I; Gonçalo M
    Contact Dermatitis; 2018 Apr; 78(4):281-286. PubMed ID: 29399806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalized reactions during skin testing with clindamycin in drug hypersensitivity: a report of 3 cases and review of the literature.
    Papakonstantinou E; Müller S; Röhrbein JH; Wieczorek D; Kapp A; Jakob T; Wedi B
    Contact Dermatitis; 2018 Apr; 78(4):274-280. PubMed ID: 29356000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of skin testing in the investigation of cutaneous adverse drug reactions.
    Barbaud A; Reichert-Penetrat S; Tréchot P; Jacquin-Petit MA; Ehlinger A; Noirez V; Faure GC; Schmutz JL; Béné MC
    Br J Dermatol; 1998 Jul; 139(1):49-58. PubMed ID: 9764148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute generalized exanthematous pustulosis induced by clindamycin.
    Kapoor R; Flynn C; Heald PW; Kapoor JR
    Arch Dermatol; 2006 Aug; 142(8):1080-1. PubMed ID: 16924073
    [No Abstract]   [Full Text] [Related]  

  • 16. Patch Testing in Drug Eruptions: Practical Aspects and Literature Review of Eruptions and Culprit Drugs.
    de Groot AC
    Dermatitis; 2022 Jan-Feb 01; 33(1):16-30. PubMed ID: 35029348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral provocation tests in non-immediate mild cutaneous reactions related to beta-lactam antibiotics.
    Vezir E; Dibek Misirlioglu E; Civelek E; Capanoglu M; Guvenir H; Ginis T; Toyran M; Kocabas CN
    Pediatr Allergy Immunol; 2016 Feb; 27(1):50-4. PubMed ID: 26619970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patch testing in fixed drug eruptions--a 20-year review.
    Andrade P; Brinca A; Gonçalo M
    Contact Dermatitis; 2011 Oct; 65(4):195-201. PubMed ID: 21702758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Generalized Exanthematous Pustulosis Caused by Faropenem: A Possible Pathogenetic Role for Interleukin-23.
    Sakuragi Y; Sawada Y; Hara Y; Ohmori S; Omoto D; Haruyama S; Yoshioka M; Nishio D; Nakamura M
    Acta Derm Venereol; 2016 Feb; 96(2):265-6. PubMed ID: 26302837
    [No Abstract]   [Full Text] [Related]  

  • 20. A method for at-home lesional testing for fixed drug eruption.
    Hanson JL; Warshaw EM
    Dermatitis; 2015; 26(3):148. PubMed ID: 25984693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.